Literature DB >> 7924893

Pharmacokinetics of silybin following oral administration of silipide in patients with extrahepatic biliary obstruction.

R Schandalik1, E Perucca.   

Abstract

The pharmacokinetics of silybin, the main active component of silymarin, following administration of a lipophilic silybin-phosphatidylcholine complex (silipide) was evaluated in fourteen patients with cholestasis secondary to biliary extrahepatic obstruction. Each patient received a single oral dose of silipide (120 mg, expressed as silybin equivalents). Blood samples for high performance liquid chromatography (HPLC) determination of free (unconjugated) and total (free+conjugated) silybin were collected at frequent intervals for up to 24 h after dosing. Absorption from the gastrointestinal tract occurred rapidly, peak concentrations of free drug being observed within 3 h in most patients. Thereafter, the decline in plasma free silybin levels was relatively rapid, and at 12 h the concentration of free drug had already approached the limit of quantitation (2 ng/ml). At all sampling times, the total (free+conjugated) concentration was much higher than the free concentration. Total silybin levels reached a peak at about 3 to 4 h and persisted at relatively high values (> or = 400 ng/ml) throughout the entire sampling period. On average, the area under the curve for total silybin was more than 40-fold greater than the area under the curve for free silybin. These data suggest that extrahepatic biliary obstruction is associated with a reduced clearance of conjugated silybin, probably due to impaired excretion of the conjugate in bile.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7924893

Source DB:  PubMed          Journal:  Drugs Exp Clin Res        ISSN: 0378-6501


  7 in total

1.  Herb-drug interactions: challenges and opportunities for improved predictions.

Authors:  Scott J Brantley; Aneesh A Argikar; Yvonne S Lin; Swati Nagar; Mary F Paine
Journal:  Drug Metab Dispos       Date:  2013-12-11       Impact factor: 3.922

Review 2.  Phytochemicals for the Management of Melanoma.

Authors:  Harish Chandra Pal; Katherine Marchiony Hunt; Ariana Diamond; Craig A Elmets; Farrukh Afaq
Journal:  Mini Rev Med Chem       Date:  2016       Impact factor: 3.862

3.  Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention.

Authors:  X Zi; R Agarwal
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-22       Impact factor: 11.205

Review 4.  Herb-drug interactions: a literature review.

Authors:  Zeping Hu; Xiaoxia Yang; Paul Chi Lui Ho; Sui Yung Chan; Paul Wan Sia Heng; Eli Chan; Wei Duan; Hwee Ling Koh; Shufeng Zhou
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Development of a HPLC-UV assay for silybin-phosphatidylcholine complex (silybinin capsules) and its pharmacokinetic study in healthy male Chinese volunteers.

Authors:  Wei Li; Jun Gao; Hong-Zhi Zhao; Chang-Xiao Liu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2006 Oct-Dec       Impact factor: 2.441

6.  A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients.

Authors:  Thomas W Flaig; Daniel L Gustafson; Lih-Jen Su; Joseph A Zirrolli; Frances Crighton; Gail S Harrison; A Scott Pierson; Rajesh Agarwal; L Michael Glodé
Journal:  Invest New Drugs       Date:  2006-11-01       Impact factor: 3.850

7.  Silymarin-loaded solid nanoparticles provide excellent hepatic protection: physicochemical characterization and in vivo evaluation.

Authors:  Kwan Yeol Yang; Du Hyeong Hwang; Abid Mehmood Yousaf; Dong Wuk Kim; Young-Jun Shin; Ok-Nam Bae; Yong-Il Kim; Jong Oh Kim; Chul Soon Yong; Han-Gon Choi
Journal:  Int J Nanomedicine       Date:  2013-08-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.